Today@Dal
» Go to news mainHelp advance cytomegalovirus (CMV) vaccine research
CCfV is now enrolling female volunteers ages 16-40 for a cytomegalovirus (CMV) vaccine clinical trial.
CMV is a common viral infection that usually goes unnoticed or only causes mild symptoms in most people. But if a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. This can cause her child to have long-term disability due to birth defects, including hearing loss, or even death in very severe cases. Currently, there is no approved vaccine against this virus.
The purpose of this clinical trial is to:
- Evaluate the safety and effectiveness of an investigational vaccine (a vaccine not yet approved by Canada's drug regulatory agency) called mRNA-1647 against cytomegalovirus (CMV) infection in women who have not had priorCMV infection and
- Evaluate its safety in women who test positive for CMV due to prior exposure.
To join this clinical trial, you must be:
- A woman between 16-40 years of age
- In good health
- Not pregnant or planning on becoming pregnant within the next 9 months
- In close contact with at least one child 5 years of age or younger for at least 8 hours a week, if age 20 or older
For more information visit the CCfV website https://bit.ly/3Z9TOby or contact:
Krystal Lariviere
Canadian Center for Vaccinology
Tel: (902) 470-8141
Email: ccfv@iwk.nshealth.ca
Recent News
- In Memoriam ‑ Colin Spinney
- Document delivery during Canada Post strike
- New surplus items added in Halifax
- Dal Tigers birthday parties
- Celebrate culture, creativity, and sustainability at the IEW Fashion Show!
- Student Accessibility Closure Friday, November 22
- Job postings
- Where suppliers can meet Dal Procurement